Immune Design Corp. (NASDAQ:IMDZ)’s share price was down 3.6% during trading on Friday . The stock traded as low as $6.66 and last traded at $6.79, with a volume of 55,874 shares traded. The stock had previously closed at $7.04.

Several equities analysts have commented on IMDZ shares. Zacks Investment Research downgraded shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Jefferies Group restated a “buy” rating and issued a $20.00 price target on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.50.

The company has a 50-day moving average price of $7.45 and a 200 day moving average price of $10.75. The stock’s market capitalization is $138.00 million.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Tuesday, August 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.03. Analysts expect that Immune Design Corp. will post ($2.70) EPS for the current year.

An institutional investor recently raised its position in Immune Design Corp. stock. Jennison Associates LLC boosted its position in Immune Design Corp. (NASDAQ:IMDZ) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,452 shares of the company’s stock after buying an additional 769 shares during the period. Jennison Associates LLC owned 1.01% of Immune Design Corp. worth $4,085,000 at the end of the most recent reporting period.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.